More than 40 companies and researchers in nanomedicine and oncology from around Spain open doors to possible collaborations
At the Biocat and CIBER-BBN "New trends in nanomedicine for oncology diagnostics and therapy" Forum, on 25 October at the PCB.
By Biocat
More than 40 companies and basic and clinical research groups from around Spain will explain their projects, experience and technology at the Industry-Academia-Clinic Forum New trends in nanomedicine for oncology diagnostics and therapy offered by Biocat and the Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), on 25 October 2012 in Barcelona. The presentations, which will be held in the morning, will be five minutes each and aim to foster direct contact among researchers, clinical professionals and business executives, as well as helping to identify common interests and possible collaborations.
To further the aim of this forum, partnering meetings will be held in the afternoon for participants interested and, among which affinities or common interests have probably been identified. To set up interviews beforehand, the organizers have provided this software (we recommend you read the instructions for use beforehand).
The inaugural addresses, at 8:55 am, will be given by Scientific Director of the Barcelona Science Park (PCB) Dr. Jesús Purroy and Carlos Lurigados, Project Director of Biocat. Afterwards, CIBER-BBN Director of Technology Transfer Dr. Fernando Santos will discuss various issues to take into account in order to make the most of participating in this event.
The workshop will be given in English.
Registration closed
Questions: Biocat (Carlos Lurigados) • clurigados@biocat.cat • Tel. +34 93 310 33 89
Date: 25 October 2012
Time: 8.30 am to 8 pm
Venue: Barcelona Science Park (PCB) • Torres R+D+I • Auditorium • C/ Baldiri Reixach, 4 • Barcelona (mapa)
- Related news (13/9/2012)
- Press release in Spanish (23/10/2012)
Lectures:
- Dr. Carles J. Ciudad, Anticancer Therapy Group (UB)
- Dr. M. Borràs, Centre of Research in Toxicology (Ceretox)
- Dr. Félix Ritort, Small System and Biomolecule Physics Group (Biosmall-UB)
- Dra. Laura Lechuga, Nanobiosensors and Bioanalytical Applications (CIN2-CSIC)
- Dr. Ibane Ibasolo, Vall d'Hebron CIBBIM-Nanomedicine
- Dra. Esther Vázquez, Applied Microbiology Research Group (IBB-UAB)
- Dr. Ramon Mangues, Oncogenesis and Antitumor Group (GOA-HSCSP)
- Dr. Ramon Eritja, Nucleic Acid Chemistry Group (GQNA-CSIC)
- Dra. Miriam Royo, Nanoparticle and Peptide Chemical Group (IRB Barcelona)
- Dr. Josep Samitier, Nanomedicine Group (NANOMED-IBEC)
- Dr. Santi Sala, Molecular Nanoscience and Organic Materials Group (Nanomol-CSIC)
- Dra. Pilar Marco, Nanobiotechnology for Diagnostics (NB4D-IQAC)
- Dr. Luis J. Fernández, Structural Mechanics and Material Modeling Group (GEMM-I3A)
- Dr. Fernando Palacio, Multifunctional Molecular Magnetic Materials Group (M4-CSIC)
- Dr. José Javier Serrano, Bioengineering and Telemedicine Group (GBT-UPM)
- Dr. Ramón Martínez, Applied Molecular Chemistry Group (IQMA-UPV)
- Dra. Alessandra Girotti, Group for Advanced Materials and Nanobiotechnology (Bioforge-UVA)
- Dr. Jesús m. Izco, CIBER-BBN Research Services
- Dr. David Fuster, Diagnosis and therapy in oncology (IDIBAPS-Hospital Clínic Barcelona)
- Dr. Victor Moreno, Colorectal Cancer Group (Idibell)
- Dr. Ander Urruticoechea, Breast Cancer (Idibell)
- Dr. Oscar Martínez, Sarcoma Research Group (Idibell)
- Dr. Marcelo Viegas, Transbiomed
- Dr. Manel Cascalló, VCN Biosciences
- Dra. Ana C. Martín, Amadix
- Dr. Nick Occleston, TCD Pharma
- Dr. Oscar P. Gulín, Argon Pharma
- Dr. Luciano Sobrevals, Endor Nanotechnologies
- Dr. Sergio Castillo, Gendiag
- Dr. Francesc Mitjans, Leitat Technological Center & Lykera Biomed
- Josep M. Escuer, NTE Sener
Organized by:
Collaborators:
| With support from: |
   |